113 related articles for article (PubMed ID: 38785480)
1. Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors.
Hummel L; Ameri M; Alqahtani S; Sadighi Z; Al-Zubidi N
Curr Oncol; 2024 May; 31(5):2644-2649. PubMed ID: 38785480
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
3. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
4. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
5. Impact of trametinib on the neuropsychological profile of NF1 patients.
Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
[TBL] [Abstract][Full Text] [Related]
6. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
9. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
10. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma.
Barrière S; Faure-Conter C; Leblond P; Philippe M; des Portes V; Lion François L; de Bellescize J; Sabatier I
Epileptic Disord; 2024 Feb; 26(1):133-138. PubMed ID: 37983638
[TBL] [Abstract][Full Text] [Related]
11. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
12. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS
Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592
[TBL] [Abstract][Full Text] [Related]
13. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
14. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
15. Sustained Tumor Control With MAPK Inhibition in
Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
17. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
19. The incidence and characterization of weight gain associated with MEK inhibitors in pediatric patients.
Rush C; Sabus A; Bradley ZK; Herbert M; Hemenway M
Pediatr Blood Cancer; 2023 Apr; 70(4):e30182. PubMed ID: 36715441
[TBL] [Abstract][Full Text] [Related]
20. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]